Recently Featured

Podcast: Rare Disease Day Highlights FDA Guidance for Advancements

March 1, 2026
Ahead of Rare Disease Day, a recent podcast featuring Abigail Beaney, editor of Clinical Trials Arena, alongside Robert Barrie and Frankie Fattorini from Pharmaceutical Technology and GlobalData Insights, delves into pivotal developments in the rare disease sector. The discussion centers on the FDA’s newly issued guidance, which aims to streamline the drug development process for…

Quotient and Ipsen Extend Partnership for Ultra-Rare Disease Therapy

March 1, 2026
Quotient Sciences has announced the extension of its commercial partnership with Ipsen, aimed at enhancing the production of Sohonos, a therapy for fibrodysplasia ossificans progressiva (FOP), a rare and debilitating condition. This collaboration underscores the growing importance of specialized therapies in addressing ultra-rare diseases, which often lack sufficient treatment options. The extension of this partnership…

Innovative Biomedical Research Takes Center Stage in STAT Madness 2026

March 1, 2026
A genetic test that diagnoses ALS and predicts survival times, a new mechanism elucidating how the sleeping brain eliminates waste proteins linked to Alzheimer’s, and dental floss capable of tracking cortisol levels represent just a fraction of the groundbreaking innovations showcased in STAT Madness 2026. This annual competition highlights the most significant biomedical and health…

New Hope Emerges for Rare Disease Treatments Amidst Development Challenges

March 1, 2026
Recent advancements in the research of rare genetic diseases, particularly CLN3 juvenile Batten disease, have sparked renewed optimism among affected families and the pharmaceutical industry. This condition, which severely impacts vision, memory, and mobility, has long been viewed as a formidable challenge due to the complexities involved in drug development. Historically, potential therapies have faced…

Ongoing Cases